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We have found a correlation between the certain characteristics ofprimary structure and biologic activity in exorphins and endogenous opioid 
peptide family. The characteristics of primary structure are the content of certain segment pairs as well as the density of their arrangement i  a 
peptide. These segment pairs represent basic elements of the regulatory peptide primary structure pattern, which was found recently lDokl. Aired. 
Nauk USSR 289 (1986) 721-724; Int. J. Peptide Prot. Res. 38 (1991) 505-510]. 
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1. INTRODUCTION 
In recent papers the pattern found for amino acid 
alternations in regulatory peptides was reported [i,2]. 
Regulatory peptides were represented asa sequence of 
hydrophobic and hydrophilic segments. The segments 
were respectively classified into 2 and 3 different ypes 
according to the peculiarities of mutual ocalization of 
hydrophobic and hydrophilic amino acid residues 
within the peptide primary structure. When compared 
with proteins, nonregulatory peptides and a random 
sequence of segments, the regulatory peptides were 
characterized by an increased frequency of 4 particular 
pairs of segments among 12 theoretically possible pairs. 
These 4 pairs represent the fra~maaents of a periodical 
segment sequence with a period of 4. The observed 
pattern indicates that there exists a general principle for 
the primary structure organization of regulatory pep- 
tides and possibly a common type of their flexible pep- 
tide chain folding at the ligand-receptor complex for- 
mation. However, causal relationship of the pattern and 
the ability of regulatory peptides for specific binding to 
receptors i still unclear. 
To analyze how certain segment combinations in reg- 
ulatory peptides are related to their biologic activity we 
investigated primary structure-activity relationship 
using a statistical approach. We have attempted to find 
a relationship between the content of the characteristic 
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pairs of segments and the biological activity of exor- 
phins and endogenous opioid peptides. Thus, the largest 
group among biologically active peptide families was 
chosen for analysis. 
For a more detailed consideration of the regulatory 
peptide primary structure pattern we should also de- 
scribe here the features of mutual localization of amino 
acid residues and the classification of the segments in 
regulatory peptides. It was found [1,2] that hydrophobic 
residues Pro, Tyr, lie, Val, Trp and Cys (group P') more 
often precede an adjacent Gly or Asn (group G" of 
hydrophilic residues) than follow them. The G" residues 
more frequently precede, than follow another group of 
hydrophobic residues (Phe, Leu, Ala and Met - group 
F'). The F' group more frequently precedes Arg, Ser, 
Thr and Lys (group R' of hydrophilic residues) rather 
than follows them, and, finally, R' group more fre- 
quently precedes than follows the P' group. The seg- 
ments of regulatory peptides ~vere. classified into 2 hy- 
drophobic (<P'>, <F'>) and 3 hydrophilic (<G'>, 
<R'> and <B'>) types according to their amino acid 
content [1,2]. Segment <P'> contains P', and other hy- 
drophobic residues; segment <F'> consists of F" resi- 
dues; segment <G'> contains G' and other hydrophilic 
residues; segment <R'> contains R' and other hydro- 
philic residues, but not G', segment <B'> consists of 
Glu, Gin, His, and Asp. We have observed that regula- 
tory peptides are characterized by an increased fre- 
quency of 4 particular pairs of segments <P'>-<G'>, 
<G'>-<F'>, <F'>-<R'> and <R'>-<P'>) which are the 
fragments of periodical segment sequence -<P'>-<G'>- 
<F'>-<R'>-<P'>-. ,,, '~ ,ho,,,,. pr~ent st,.a.3 , . .  w,'.......h'~,," USed 
this amino acid and segment classification to reveal (a) 
the features of the primary structure of the peptides 
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interact ing with op io id  receptors  and (b) an assoc iat ion 
between the features and  b io logica l  act iv i ty  o f  the pep- 
tides. 
2. METHODOLOGY,  METHODS AND DATA 
The peptides chosen for this study are naturally occurring opioids, 
exorphias and endogenous opioid peptides consisting of L-amino acid 
residues and exerting their action through opioid receptors (Table 1), 
Recent studies [1,2] have demonstrated that with regard to their 
chain-length distribution, regulatory peptides may be divided into two 
g,'oups: the group of short regulatory peptides with a length of up to 
20 residues and the group of long regulatory peptides containing over 
20 residues, The pattern of segment alternations was revealed for the 
short regulatory peptides, Long regulatory ~ptides do not fit to the 
pattern go well: the quantitative differences between this group a,ad a 
random segment sequence were weaker compared to the group of 
short peptides. Therefore, in further considerations only peptides con- 
taiuing le~s than 20 residues were selected. 
In accordance with our previous approach [1,2] we here classify 
residues Pro, Tyr, Val, lie, Trp, Cys as P'; Phe, Leu, Ala, Met as F'; 
Are, Ser, Thr, Lys as g'; Gly, Ash as G': Asp, Glu. His, Gin as B'. 
The segments cntaining P' and F'  are referred to as <P'>; containing 
F' as <F'>; containing (3', R' and B' as <G'>; those containing R' and 
B' as <R'>, and those consisting of B' as <B'>. 
To characterize the ability of the peptides to interact with opioid 
receptors we have used lC~o and K~ (or .%) values obtained in pharma- 
cological assays on isolated electrically stimulated tissues (guinea pig 
ileum (GPI), mouse or rat vas deferens (M/RVD)), and in biochemical 
binding assays, respectively (Table 1), To reveal the general properties 
of the peptides in the sample we have only taken the maximal value 
o1" biological activity obtained in either one of three isolated tissue 
preparations or in the binding assays described. The maximal value 
of actNity reflects the principal ability of peptides to interact with 
receptors independently of whether there are several types of opioid 
receptors or not. The mean value of the parameters was calculated 
using data from the papers indicated (Table i). 
Correlations were generated by regression analysis fitting the best 
straight line via the least-squares method and a t-test was used in order 
to test the significance of" the observed association. Since we have no 
evidence that the scores us~ were from a bivariate normal population 
we also applied a nonparametric technique for measuring the degree 
of correlation between the different variables (Spearman rank correla- 
tion coefficient, rs) and its significance, 
3, RESULTS AND DISCUSSION 
Tab le  1I shows the segment pairs o f  op io id  pept ides 
which occur  at a h igher  rate than in a random sequence 
Table 1 
Exorphins and endogenous opioid pmptides, Amino acid and segment sequences and biological activity 
Peptides Amino acid sequence Segment sequence Characteristic Biological activity' References 
segment pairs, 
No. 
OPl, M/RVD. Binding assay, 
-iogtlC,ol (M) -log[K,:d (M) 
Cytochrophin..4 YPFT <P'R'> 0 3.9 4,5 
Hemorphin-4 YPWT <P'R'> 0 4,4 5 
Morphiceptin YPFP-NH_~ <P'> 0 6.2 7.5 3,7,18 
h.fl.Caso,'aorphin-5 YPFVE <P'B'> 0 4.6 4.7 4,14 
b-,~-Casomorphin-5 Y PFPG <P'G'> 1 5.9 6.4 4,5,7,14 
Cytochrophin-5 YPFTI <P'R'P'> 1 3.5 4,5 
Hemorphia-5 YPWTE <P'R'> 0 4.3 5 
Leu-enkephalin YGGFL <P'G'F '> 2 8.0 8.5 6,8,10,15,23,24,27 
Met-enkephalin YGGFM <P'G'F'> 2 7,8 8,7 6,9,15,19,24,25,27 
cz.Casein (90-95) RYLGY <R'P'G'P'> 2 4.2 6,1 16 
~x-Casein (91-96) YLGYL <P'G'P'> 1 5,0 16 
Leu-enkephalinR ° YGGFLR <P'G'F'R'> 3 7.5 10,17,19,22,23 
h.fl.Casomorphin-7 YPFVEPI <P'B'P'> 0 4..5 15,2 14 
b-fl-Casomorphin-7 YPFPGPi <P'G'P'> 1 5.3 4,6 7,14 
a-Casein (90-96) RYLGYLE < R'P'G'P'B'> 2 4.5 6,8 16 
Met-gnkephalinR~F 7 YGGFMRF <IVG'F"R'F'> 3 8.3 %6 17,19,27 
h.fl-Casomorphin-fl YPFVEPIP <P'B'P'> 0 4.8 5,2 14 
b-//.Casomorphilt-8 YPFPGPIP <P'G'P'> i 5.5 4,2 14 
Met-enkephalin R6G~L ~' YGG FM RG L <P'G'F'G'F'> 3 8,5 8.3 17,19 
Dynorphin A (I-8) YGGFLRRI <P'G'F'R'P'> 4 8,3 8,9 10 
Metorphamide YGGFMRRV-NH2 <P'G'F'R'P'> 4 8,6 9.9 26 
p-Neoendorphin YGGFLRKYP <P'G'F'R'P'> 4 7,9 8,9 12,21,22 
=-Neoendorphin YGGFLRKYPK <P'G'F'R'P'R'> 4 7,9 9,7 10,12,21 
Dynorphin B YGGFLRRDFKVVT <P'G'F'R'F'R'IVR'> 15 8,8 9.9 12,13,22 
Dynorphin A 
(1-13) YGGFLRRIRPKLK <P'G'F'R'P'R'P'R'F'R'> 6 9,1 10 .3  8,10-12,20 
~x-Endorphin YGGFMTSEKSDTPLVT <P'G'F'R'P'R'> 4 7,6 7.0 9,10,21,25 
7.-Endorphin YGOFMTSEKSDTPLVTL <WG'F'R'P'R'F'> 4 7,6 7.2 21,25 
Dynorphin A 
(1-17) YOGFLRRIRPKLKWDNQ <WG'F'R'P'R'P'R'F'R'P'G'> 8 9.5 9.9 10,22 
"The maximal values of the parameters were selected or mean maximum values of those were calculated using data from the papers indicated. 
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Table 11 
The segment pairs of which the content in opioid peptides, as well as 
in regulatory peptides, exceeds that in random segment sequences 
(" data taken from [I,2]), The ratio of segment pair frequency in the 
peptides to segment pair sequence in a random segment sequence is
given, The relative content of segments oF various types in a random 
segment sequence and in opioid peptides wa~ assumed to be the ~m¢, 
Analysis was performed and data are presented as described previ- 
ously [2] (Table Ill): 'P < 0.01, "'P < 0,001, ""P < 0,0002. 
Table ill 
Relationship between biologic activity (-log tiCs0 or K~ (Kd)l) and 
properties of primary structure of the peptides. Coefficient of correla- 
tion (r) and Spearman rank correlation coefficient (rs; values corrected 
for tics are shown in brakers). 
Numbers (n)/peptide Activity in tissue Activity in binding 
preparations assay 
r r3  r r5  
Segment pair type Opioid peptid¢~ Regulatory peptides" 
<P'>-<G'> 1.34 °. 1.20"" 
<G'>-<F'> 1.58" 1.38"" 
<F'>-<R'> 1.87"" 1.59"" 
<R'>-<P'> 1.43" 1.26"" 
o f  segments. When compared to a random segment se- 
quence, opioid peptides (like short regulatory peptides 
[1,2]) l lave a significantly higher occurrence rate o f  the 
fol lowing segment pairs: <P '>-<G'>,  <G'>-<F '>,  
<F '>-<R'> and <R'>-<P '>.  In conformi ty  with what 
was found for the short  regulatory peptides these pairs 
Amino acids, n 0.59 0.62 0.40 0,44 
Segment pairs, n 0.70 0.67 0.63 0.62 
Characteristic segment 0.86 0,80 (0,84) 0.80 0,79 (0.82) 
pairs, n 
Ratioofnofsegment pairs/ 0.59 0.57 0.57 0,58 
n of amino acids 
Ratioofn of characteristic 0.85 0.76 (0.79) 0.82 0,85 (0.85) 
segment pairs/, of amino 
acids 
Ratio ofn orcharacmristic 0.79 0.65 0.70 0.64 
segment pair~n of segment 
pairs 
o f  segments are the fragments o f  a hypothet ic  periodical 
sequence -<P '>-<G'>-<F '>-<R'>-<P '>.  
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FiB. 1. Relationship between the biological activity and the number of characteristic segment pairs in peptide (A,C) or the ratio of the number 
of characteristic segment pairs to the number of amino acid in pcptid¢ (B,D). The IC~ values (A,B) were determined in pharmacological assays 
on isolated tissue and K~ (or Ka) values were determiaed in biochemical binding assays (data were taken from the papers indicated, s¢¢ Table !). 
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The analysis of the relationship between the biologi- 
cal activity of the peptides and parameters describing 
the properties o f  their primary structure showed that the 
best association occurs between the biological activity 
and the number of  characteristic segment pairs in the 
peptide (r = 0.80-0.86, P < 0.00001; rs  = 0.79-0.80, 
P < 0.001) (Fig. 1; Table 111). This holds true for the 
relationship of  the biological activity and the ratio of 
the number of  characteristic segment pairs to the num- 
ber of  amino acid residues in peptide (r = 0.82-0.84, 
P < 0.00001; rs  = 0.76-0.85, P < 0.001) (Table 1II, Fig. 
1). 
Thus, the higher the number of  characteristic segment 
pairs in the opioid peptide, the higher its biological 
activity (receptor affinity). The same is found for the 
ratio of  the number of  characteristic segment pairs and 
the number of  amino acids in the peptide (i.e. the den- 
sity of  arrangement of  characteristic segment pairs 
along a peptide sequence) and the biological activity. It 
has been assumed that the peptide containing the ob- 
served periodical sequence of  segments may form a 'reg- 
ular' three-dimensional structure [2]. The structure of  
each regulatory peptide at the l igand-reeeptor complex 
may be a fragment of  this 'regular' structure. Regarding 
the present results, it seems likely that the higher the 
number and density of  characteristic segment pairs in 
a peptide, the better it can fit to this three-dimensional 
structure, resulting in higher biological activity. 
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